Brennan Paul N, Dillon John F, McCrimmon Rory
The University of Edinburgh, Centre for Regenerative Medicine, Edinburgh, UK.
NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.
touchREV Endocrinol. 2022 Nov;18(2):148-155. doi: 10.17925/EE.2022.18.2.148. Epub 2022 Nov 22.
Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting and positive developments in this landscape, although there are inherent challenges ahead. In this article, we review the aetiological and pathological basis of NASH progression and describe putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and challenging disease paradigm.
非酒精性脂肪性肝炎（NASH）现已成为肝硬化和肝细胞癌最常见的形式之一。在动物模型中取得了令人鼓舞的结果后，多种治疗药物已在人体中进行了评估。目前，约有50种治疗药物正处于不同的研发阶段。然而，尽管未来仍存在内在挑战，但最近在这一领域已出现了许多令人振奋的积极进展。在本文中，我们回顾了NASH进展的病因学和病理学基础，并描述了当前疗法的假定靶点。我们还讨论了围绕这一复杂且具有挑战性的疾病模式的一些可能的未来方向和困难。
